Related Experiment Video

Updated: Aug 17, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity

F Habens1, N Srinivasan, F Oakley

  • 1Cancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, University of Southampton, SO16 6YD, UK.

Apoptosis : an International Journal on Programmed Cell Death
|May 24, 2005
PubMed

Insights

New sulfasalazine (SFZ) analogues effectively inhibit nuclear factor-kappa B (NF-kB) activity and promote apoptosis. These SFZ derivatives show promise as therapeutic agents for cancers and chronic liver diseases.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • Nuclear factor-kappa B (NF-kB) is a transcription factor crucial for regulating apoptosis and cell survival.
  • Dysregulated NF-kB activity contributes to various human diseases, including malignancies and chronic liver disease.
  • Small molecule inhibitors targeting NF-kB represent a potential therapeutic strategy.

Purpose of the Study:

  • To synthesize and evaluate novel sulfasalazine (SFZ) analogues as inhibitors of NF-kB.
  • To assess the ability of these analogues to induce apoptosis in cancer and liver cells.
  • To identify SFZ derivatives with enhanced anti-NF-kB and pro-apoptotic activities.

Main Methods:

  • Synthesis of six sulfasalazine analogues.
  • Assessment of NF-kB dependent transcriptional activity inhibition.
  • Evaluation of apoptosis induction in chronic lymphocytic leukemia and hepatic stellate cells.

Main Results:

  • Three out of six synthesized SFZ analogues demonstrated significantly enhanced inhibition of NF-kB dependent transcription (up to 8-fold).
  • Increased NF-kB inhibitory activity correlated with enhanced apoptosis induction in tested cell lines.
  • Sulfasalazine (SFZ) itself inhibited NF-kB activation, but its analogues showed superior efficacy.

Conclusions:

  • Sulfasalazine analogues can be readily synthesized to improve NF-kB inhibitory activity.
  • Enhanced SFZ derivatives hold potential as therapeutic agents for NF-kB-driven malignancies and chronic liver diseases.
  • Targeting NF-kB with novel SFZ analogues offers a promising avenue for disease treatment.

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...